|
Randal J. Kirk - Founder, Chairman
of the Board, President & Chief Executive Officer
 |
Mr. Kirk is our founder and has served as a director since
August 1996, as Chairman of the Board since 1996 and as President
and Chief Executive Officer since October 2001. Mr. Kirk has
over 20 years of experience in the health-care industry. Previously,
Mr. Kirk co-founded General Injectables & Vaccines, Inc.,
a pharmaceutical distributor (GIV), in 1983 and served as
Chairman of the board of GIV prior to the sale of that company
in 1998. Mr. Kirk served as a member of the board of directors
of Scios, Inc. (previously traded on NASDAQ and recently acquired
by Johnson & Johnson) between February 2000 and May 2002.
Mr. Kirk also currently serves as Senior Managing Director
of Third Security, LLC, an investment management firm founded
by Mr. Kirk, since March 1999, as a member of the board of
directors of Clinical Data, Inc. (NASDAQ: CLDA) since September
2002, and as chairman of its board since December, 2004. He
has served on the board of directors of the Radford University
Foundation, Inc. since September 1998 the Virginia Bioinformatics
Institute Policy Advisory Board since March 2004, and the
Board of Visitors of Radford University since July 2003. He
serves as well on a number of other foundations. Mr. Kirk
received a B.A. in Business from Radford University and a
J.D. from the University of Virginia.
Krish S. Krishnan - Chief Operating Officer and Chief
Financial Officer
Mr. Krishnan has served as a member of our board
of directors since March 2003 and as Chief Financial Officer
and Chief Operating Officer since April 2004. He served as
President and CEO of Harvest Pharmaceuticals Inc. between
February 2003 and April 2004. Since March 2002, Mr. Krishnan
served as a Senior Managing Director of Third Security, LLC.
Previously, Mr. Krishnan was a director at a start-up venture,
Suppliermarket.com, Inc., which was sold to Ariba Technologies
Inc., in August 2000. He then served as a managing principal
of Ariba, focusing primarily in the pharmaceutical industry,
until joining Third Security, LLC in March 2002. Mr. Krishnan
was also a senior manager with A.T. Kearney, Inc., a management
consulting firm, where he advised pharmaceutical companies
on strategic and operational issues; a consultant with KPMG
Peat Marwick; and an engineer with E.I. Dupont de Nemours,
a multinational chemical company. Mr. Krishnan received a
B.S. in Mechanical Engineering from the Indian Institute of
Technology (IIT), a M.S. in Engineering from the University
of Toledo, and an M.B.A. from The Wharton School at the University
of Pennsylvania.
Garen Z. Manvelian, M.D. - Chief Medical Officer, Vice President Clinical and Regulatory Affairs
Dr. Manvelian came to New River in October 2006 from SkyePharma Inc., where he served since 2000 as Senior Director, Clinical and Medical Affairs. Prior to that, he served as a Clinical Research Scientist at Quintiles CNS Therapeutics.
Dr. Manvelian holds an M.D. degree from the Vitebsk State Medical Institute in Vitebsk, Belarus. He completed a residency program in anesthesiology at the Republic Hospital of Armenia in Yerevan, Armenia, and a postdoctoral fellowship at the Yale University School of Medicine Department of Anesthesiology
John K. Thottathil, Ph.D. - Chief Scientific Officer
New River Pharmaceuticals Inc. welcomed Dr. Thottathil as
its Chief Scientific Officer in April, 2006. Prior to joining
New River, Dr. Thottathil served for over four years as the
Director of Core Research and Development Chemistry, Diagnostic
Division, at Abbott Laboratories. Prior to that, he worked
at Bristol-Myers Squibb for 19 years in a variety of positions,
most recently as Director of Outsourcing, Worldwide Process
Research and Development, and earlier as Director of Chemical
Process Research Departments in New Brunswick, NJ and Candiac,
Canada. Several of his projects resulted in product launches;
he has contributed to 60 patents, and has authored or co-authored
more than 40 peer-reviewed publications.
He holds a Doctor of Philosophy degree in Organic Chemistry
from the Indian Institute of Science in Bangalore, India,
and conducted post-doctoral research at Yale University in
New Haven, Connecticut, and Emory University in Atlanta, Georgia.
Suma M. Krishnan - Vice President, Product Development
Mrs. Krishnan has 14 years experience in drug development.
Mrs. Krishnan has been Vice President, Product Development
at New River Pharmaceuticals Inc. since September 2002. Prior
to joining New River Pharmaceuticals, Mrs. Krishnan served
in the following capacities: Director, Regulatory Affairs
at Shire Pharmaceuticals, Inc., a specialty pharmaceutical
company; Senior Project Manager at Pfizer, Inc., a multi-national
pharmaceutical company; and a consultant at the Weinberg Group,
a pharmaceutical and environmental consulting firm. Mrs. Krishnan
began her career as a discovery scientist for Janssen Pharmaceuticals,
a subsidiary of Johnson & Johnson, a multi-national pharmaceutical
company, in May 1991. Mrs. Krishnan received a M.S. in Organic
Chemistry from Villanova University, an M.B.A. from Institute
of Management and Research ( India ) and an undergraduate
degree in Organic Chemistry from Ferguson University ( India
).
Samir D. Roy, Ph.D. – Vice President, Formulation
and Manufacturing
Dr. Roy joined the New River Pharmaceuticals Inc. team as
its Vice President, Formulation and Manufacturing in August,
2006. Immediately prior to joining New River, Dr. Roy served
as the Executive Director of Product Research at Watson Pharmaceuticals
Inc. In his nearly twenty years in the pharmaceutical industry,
he has held positions with Insite Vision Inc., Pfizer-Agouron
Pharmaceutical Inc., Roche Pharmaceuticals, and Cygnus Therapeutics
Inc. He has authored or co-authored more than 25 journal articles,
is listed on ten U.S. patents, and has been involved in the
development of a number of FDA product approvals.
Dr. Roy holds a Ph.D. degree from the College of Pharmacy,
University of Saskatchewan in Saskatoon, Canada, with a research
focus on the oral absorption of amphetamines and its analogs:
drug metabolism, bioanalytical method development and PK modeling.
He conducted a post-doctoral fellowship at the University
of Michigan College of Pharmacy in Ann Arbor, Michigan, with
a research focus on physicochemical characterizations of narcotic
analgesics, skin transport mechanism, transdermal formulations
for preclinical/clinical trials. He also holds a B.S. degree
in Pharmacy from the BHU Institute of Technology, India.
Clifton R. Herndon II - Vice President, Finance and
Controller
Mr. Herndon has served as our Controller since May
1999 and was recently elected as Vice President, Finance.
He also has served as a Managing Director with Third Security,
LLC, an investment management firm, since September 1999.
Previously, Mr. Herndon served as the Director of Financial
Operations for Biological & Popular Culture, Inc., an
affiliate; as Assistant Controller for General Injectables
& Vaccines, Inc., a pharmaceutical distributor, from November
1997 through December 31, 1998; as Assistant Controller and
Cost Accounting Manager with Long-Airdox Company, a manufacturer
of mining equipment, from May 1996 to November 1997; and as
a Manager with Ernst & Young, LLP from October 1994 to
May 1996. Mr. Herndon began his career with Ernst & Young,
LLP in July 1989. Mr. Herndon received a B.B.A. in Accounting
from Marshall University.
|
